Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Oral antibodies to human papillomavirus type 16 in women with cervical neoplasia
Journal of Medical Virology, Volume 65, No. 1, Year 2001
Notification
URL copied to clipboard!
Description
This study investigated the relationship between human papillomavirus type 16 (HPV-16) antibodies detected in oral fluid from women with cervical neoplasia, their HPV-16 antibody seroprevalence, and their cervical HPV-16 DNA presence. Cervical HPV-16 DNA was detected by polymerase chain reaction in 43.2% (35/81) of these women. The prevalence of IgG and IgA antibodies to HPV-16 virus-like particles (VLP-16) in oral fluid and was investigated by enzyme-linked immunosorbent assay. Anti-VLP-16 IgA antibodies were detected in oral fluid from 54.3% (44/81) of women with cervical neoplasia, compared with 8% (3/36) in controls (P= 0.000002). Anti-VLP-16 IgG was detected in oral fluid from 43.2.9% (25/72) and 13.3% (4/30; P=0.029), respectively. Women who were HPV-16 DNA positive at their cervical lesion, displayed an oral fluid anti-VLP-16 IgA prevalence of 60.7% (17/28) and HPV-16 DNA negative women an oral fluid anti-VLP-16 IgA prevalence of 50% (20/40; P=0.38). Oral fluid anti-VLP-16 IgG prevalence in HPV-16 DNA positive women was 28.6% (8/28) compared with 40% (16/40) in oral fluid from HPV-16 DNA negative women (P= 0.3). Amongst HPV-16 DNA positive women, the anti-VLP-16 IgG seroprevalence was 75% (21/28) and IgA seroprevalence 35.7% (10/28) and for the HPV-16 DNA negative women these values were 60% (24/40) and 32.5% (13/40), respectively. Oral IgA antibody testing proved no more sensitive than serum antibody detection for the determination of HPV infection but could be useful as a non-invasive screening method for women with cervical neoplasia and for estimating the mucosal antibody response to HPV vaccines. © 2001 Wiley-Liss, Inc.
Authors & Co-Authors
Marais, Dianne Jean
South Africa, Cape Town
Faculty of Health Sciences
Best, Jennifer M.
United Kingdom, London
St Thomas' Hospital
Rose, Robert C.
United States, Rochester
University of Rochester School of Medicine and Dentistry
Keating, Patrick
South Africa, Cape Town
Faculty of Health Sciences
United Kingdom, Preston
Lancashire Teaching Hospitals Nhs Foundation Trust
Soeters, Robbert Paul
South Africa, Cape Town
Faculty of Health Sciences
Denny, Lynette A.
South Africa, Cape Town
Faculty of Health Sciences
Dehaeck, Catherine M.C.
South Africa, Cape Town
Faculty of Health Sciences
Nevin, James
South Africa, Cape Town
Faculty of Health Sciences
Kay, Patti
South Africa, Cape Town
Faculty of Health Sciences
Passmore, Jo Ann Shelley
South Africa, Cape Town
Faculty of Health Sciences
Williamson, Anna Lise
South Africa, Cape Town
Faculty of Health Sciences
Statistics
Citations: 37
Authors: 11
Affiliations: 4
Identifiers
Doi:
10.1002/jmv.2014
ISSN:
01466615
Research Areas
Cancer
Genetics And Genomics
Health System And Policy
Study Design
Cross Sectional Study
Participants Gender
Female